tients with cirrhosis and is associated with increased rate of other complications such as gastrointestinal bleeding, spontaneous bacterial peritonitis, and hepatic encephalopathy 1) . The presence of ascites predicts poor clinical outcome in cirrhotic patients, as shown by the 3-year survival rate for patients with ascites at 50% 2) . Progressive liver failure and superimposition of precipitating events culminate in the development of HRS, a state of severe intrarenal vasoconstriction and reduced GFR without intrinsic renal damage. Survival of patients with liver disease continues to be affected by the presence of renal dysfunction, even after they underwent liver transplantation 3) . liver disease. Better understanding of the pathophysiology enabled clinicians to introduce effective therapies for renal dysfunction once considered irreversible or medically intractable, and led to the proposal of new concepts and diagnostic criteria for HRS 4) .
Renal dysfunction in cirrhosis is
Pathophysiology of renal dysfunction in chronic liver disease
Peripheral arterial vasodilatation and hyperdynamic circulation in chronic liver disease
Portal hypertension in cirrhosis is one of the best examples of hyperdynamic circulation, which results from a combination of increased cardiac output and dilated peripheral vascular bed 5) . Investigators have been aware of the importance of primary vasodilatation in cirrhosis for a long time, and bedside observation made by astute clinicians describes the typical features of hyperdynamic circulation in patients with cirrhosis, including increased pulse pressure, warm extremities, and capillary pulsations in the nail bed. Based on these findings, Kowalski and Abelmann
were the first to demonstrate an increase in cardiac output and a decrease in peripheral vascular resistance in a patient with alcoholic cirrhosis 6) . A subsequent study corroborated this finding 7) . In addition, a host of studies using Doppler ultrasonography to assess blood flow in various organs in patients with cirrhosis have demonstrated (1) the state of hyperdynamic circulation in chronic liver disease, (2) predominant vasodilatation in the splanchnic vessels, and (3) relative vasoconstriction in other organs such as the kidneys 8, 9) .
Splanchnic and systemic vasodilatation in the wake of portal hypertension creates a state of relative hypovolemia, which activates sodium-conserving mechanisms and leads to an increase in plasma volume. Most of the increase in plasma volume is used to fill up the increased splanchnic vascular compartment. Meanwhile, portal blood flow increases in the face of increased intrahepatic vascular resistance, as portosystemic collaterals partially decompress the portal vein and provides conduits for pooled splanchnic blood. The importance of increased blood flow in the portal vein was shown in a previous study, which reports that an increase in portal venous flow is a major contributing factor in maintaining and aggravating portal hypertension in conditions of increased intrahepatic resistance 10) .
Alterations in renal function
Splanchnic and systemic vasodilatation leads to renal vasoconstriction and impaired renal function (Fig. 1 ).
Relative hypovolemia activates the sympathetic nervous system and renin-angiotensin-aldosterone system, and increases nonosmotic secretion of arginine vasopressin (AVP), resulting in sodium and water retention and development of ascites and hyponatremia. Renal hypoperfusion and cardiac dysfunction combine to provoke severe intrarenal vasoconstriction leading to HRS.
The clinical course of renal impairment in cirrhosis is .
Pathogenesis of splanchnic arterial vasodilatation
In vivo and in vitro studies have investigated the mechanisms of splanchnic vasodilatation in chronic liver disease by using experimental animal models for cirrhosis. Major findings from these studies are as follows: (1) ; (4) and inhibition of NO synthesis almost completely normalize major hemodynamic abnormalities and renal function 16, 17) . Vascular hyporesponsiveness and increased NO production were observed in major systemic arteries as well as in splanchnic arteries 18, 19) .
Nitric oxide is believed to be a key player in patho- Increased NO production leads to splanchnic and systemic arterial vasodilatation, which, combined with increased effective arterial blood volume, increases blood flow and augments NO production, as an increase in blood flow is a well-known stimulus for NO synthases (Fig. 2 ).
As mentioned before, portosystemic shunts have a significant role in maintaining or aggravating hyperdynamic circulation, and increased portal blood flow can enhance the production of NO in the splanchnic circulation. Circulating hormones (e.g., endocannabinoids), gastrointestinal hormones (e.g., glucagon), and proinflammatory cytokines (e.g., tumor necrosis factor-alpha) induced by bacterial translocation can contribute to increased NO production [23] [24] [25] .
There are NO-independent mechanisms involved in hyperdynamic circulation in cirrhosis, as knockout of eNOS did not completely prevent the development of hyperdynamic circulation in portal hypertension 26) . Studies on subsequently diminished production of IP3 and DAG; reduced activity of DAG-dependent protein kinase C; and reduced rhoA activity [27] [28] [29] .
Clinical manifestations
Hyponatremia, ascites, and HRS are among the principal clinical consequences of the progressive arterial vasodilatation and hyperdynamic circulation in cirrhosis.
Impaired sodium excretion and free water clearance result in the development of hyponatremia and ascites, and progressive decrease in GFR results in the development of HRS.
Progression of renal dysfunction in cirrhosis can be divided into five stages (Table 1) 30)
. In the early phase of liver dysfunction (stage 1), patients can excrete daily sodium intake, though just in the range of normal daily sodium intake, and show normal GFR and absence of ascites.
In the next phase of renal dysfunction (stage 2), impaired .
Management

Hyponatremia
Restriction of free water intake is the mainstay of treatment for hyponatremia. Severe symptomatic hyponatremia should be managed with hypertonic saline infusion.
However, both treatments are not aimed to address the underlying pathophysiology of water retention, the nonosmotic AVP secretion.
Pharmacologic inhibition of AVP action is emerging as a valuable addition to the armamentarium for management of hypervolemic or euvolemic hyponatremia. Binding to V2 receptor on the basolateral surface of the collecting tubular epithelial cells, V2 receptor antagonists (vaptans) inhibit the action of AVP and increase free water clearance.
Several studies on cirrhotic patients with ascites and hyponatremia showed that V2 receptor antagonists increased urinary excretion of free water and plasma sodium concentration and were not associated with increased rates of serious adverse events [33] [34] [35] . A multi-center, randomized, placebo-controlled trial on 110 patients with ascites and hyponatremia reported that satavaptan improved the control of ascites, moderately increased plasma sodium concentration, and was not associated with significant alterations in plasma and urine electrolyte concentrations 33) . Patients who start on V2 receptor antagonists may require admission, as clinical trials with tolvaptan showed that a small fraction of patients (~2%) had early-stage increases in plasma sodium concentration higher than the acceptable range 35) .
Ascites
To counterbalance sodium retention in cirrhosis, negative sodium balance should be achieved by reducing daily sodium intake to less than 2 g/d and by starting diuretic 
Hepatorenal syndrome
An ideal treatment for HRS should be aimed at improving renal perfusion and glomerular filtration rate. It should achieve (1) reduction of serum creatinine to less than 1.5 mg/dL, (2) prolongation of survival, and (3) [36] [37] [38] [39] . The available vasoconstrictors proven to be effective in clinical trials are vasopressin analogues (e.g., terlipressin, ornipressin) 36, 37) , midodrine plus octreotide 38) , and norepinephrine 39) . Com- Table 2 . .
Prevention of HRS
Norfloxacin was associated with decreased one-year probability of SBP and HRS, and improved 3-month survival. 
